In the BioHarmony Drug Report Database

"Preview" Icon

Ivacaftor

Kalydeco (ivacaftor) is a small molecule pharmaceutical. Ivacaftor was first approved as Kalydeco on 2012-01-31. It is used to treat cystic fibrosis in the USA. It has been approved in Europe to treat cystic fibrosis. It is known to target cystic fibrosis transmembrane conductance regulator. Kalydeco’s patents are valid until 2033-02-27 (FDA).

 

Trade Name

 

Kalydeco
 

Common Name

 

ivacaftor
 

ChEMBL ID

 

CHEMBL2010601
 

Indication

 

cystic fibrosis
 

Drug Class

 

Cystic fibrosis transmembrane regulator (CFTR) protein modulators

Image (chem structure or protein)

Ivacaftor structure rendering